Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 4 art units • 8 examiners • 0 of 10 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Arbor Biotechnologies Inc. has 10 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 8 distinct examiners and 4 distinct art units. This ratio of 10 actions to 8 examiners indicates that most examiners are handling only a single matter, though some overlap exists. The involvement of 4 distinct art units suggests that the Biotechnology & Pharmaceuticals filings are categorized into several specialized groups.
LIPPOLIS, ALEXANDRA ROSE is the busiest examiner for this company, currently overseeing 3 pending office actions. This accounts for a notable portion of the 10 pending office actions in the portfolio. Practitioners should prioritize understanding the specific tendencies of LIPPOLIS, ALEXANDRA ROSE, as her 3 actions represent the highest concentration of pending work within the 4 distinct art units. Managing 10 pending office actions across 8 distinct examiners requires a robust tracking system to maintain alignment. The 3 actions under LIPPOLIS, ALEXANDRA ROSE are the most critical single-examiner cluster for the firm to monitor.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (10%) |
| §103 only | 1 (10%) |
| §112 only | 1 (10%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 3 (30%) |
| Multi-statute (no §101) | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPOLIS, ALEXANDRA ROSE | 3 | 46.9% | +59.0% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| SU-TOBON, QIWEN NMN | 1 | 66.7% | +66.7% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| TINSLEY, BRENDAN THOMAS | 1 | 58.7% | +73.9% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 56.3% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682774 | COMPOSITIONS COMPRISING A VARIANT CAS12I3 POLYPEPTIDE AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18565567 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF | HUDSON, AMY ROSE | — |
| 18274697 | CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | LIPPOLIS, ALEXANDRA ROSE | — |
| 18274698 | CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | LIPPOLIS, ALEXANDRA ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17497725 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | DACE DENITO, ALEXANDRA GERALDINE | 45d overdue |
| 18251183 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING BCL11A AND USES THEREOF | KONOPKA, CATHERINE ANNE | 50d |
| 18682774 | COMPOSITIONS COMPRISING A VARIANT CAS12I3 POLYPEPTIDE AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18565575 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF | ZARA, JANE J | — |
| 18565567 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF | HUDSON, AMY ROSE | — |
| 18281201 | COMPOSITIONS COMPRISING A VARIANT POLYPEPTIDE AND USES THEREOF | CHONG, KIMBERLY | — |
| 18274697 | CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | LIPPOLIS, ALEXANDRA ROSE | — |
| 18274698 | CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | LIPPOLIS, ALEXANDRA ROSE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 3 |
| 1637 | 2 |
| 1635 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682774 | COMPOSITIONS COMPRISING A VARIANT CAS12I3 POLYPEPTIDE AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — | §101§112 | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18565575 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING HYDROXYACID OXIDASE 1 (HAO1) AND USES THEREOF | ZARA, JANE J | — | §112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18565567 | GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF | HUDSON, AMY ROSE | — | §102§103 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18281201 | COMPOSITIONS COMPRISING A VARIANT POLYPEPTIDE AND USES THEREOF | CHONG, KIMBERLY | 1636 | §112DP | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18274697 | CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18274698 | CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18262086 | CAS12I2 FUSION MOLECULES AND USES THEREOF | SU-TOBON, QIWEN NMN | 1636 | §103§112DP | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18251183 | COMPOSITIONS COMPRISING AN RNA GUIDE TARGETING BCL11A AND USES THEREOF | KONOPKA, CATHERINE ANNE | 1635 | §103DP | Final Rejection | 50d | Pending | Apr 28, 2023 |
| 18010680 | CELLS MODIFIED BY A CAS12I POLYPEPTIDE | TINSLEY, BRENDAN THOMAS | 1634 | §103 | Final Rejection | — | Pending | Dec 15, 2022 |
| 17497725 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | DP | Non-Final OA | 45d overdue | Pending | Oct 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial